Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma†

(2013) A. C. Roy et al.   ANNALS OF ONCOLOGY

Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010

(2013) Kyu-Won Jung et al.   Cancer Research and Treatment

Optimal indications for second-line chemotherapy in advanced gastric cancer

(2012) Hiroko Hasegawa et al.   ANTI-CANCER DRUGS

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

(2012) Jung Hun Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

(2011) Peter C. Thuss-Patience et al.   EUROPEAN JOURNAL OF CANCER

A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy

(2010) D. Kanagavel et al.   ANNALS OF ONCOLOGY

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

(2009) Sang Hoon Ji et al.   BMC CANCER

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

(2008) V Catalano et al.   BRITISH JOURNAL OF CANCER